Clinical Trial

A Study to Evaluate the Safety and Clinical Efficacy of STR-P004

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, single-center, open-label, multiple-dose, dose-escalation early clinical study aimed at evaluating the safety, tolerability, and pharmacokinetic profile of STR-P004 in subjects with relapsed/refractory CD19-positive B-cell non-Hodgkin lymphoma, and preliminarily observing its antitumor activity.
Trial Details
NCT Number NCT07003178
Lead Sponsor Starna Therapeutics
Conditions Non Hodgkin Lymphoma
Enrollment 30 participants
Start Date 2025-06
Primary Completion 2026-04 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-06-04